Performance of clinical and histological prognostic scores for kidney survival in ANCA-associated vasculitis.

IF 4.7 2区 医学 Q1 RHEUMATOLOGY
Marlon J Sandino-Bermúdez, Adriana Hernández-Andrade, Andrea Hinojosa-Azaola, Eduardo Martín-Nares, Juan M Mejía-Vilet
{"title":"Performance of clinical and histological prognostic scores for kidney survival in ANCA-associated vasculitis.","authors":"Marlon J Sandino-Bermúdez, Adriana Hernández-Andrade, Andrea Hinojosa-Azaola, Eduardo Martín-Nares, Juan M Mejía-Vilet","doi":"10.1093/rheumatology/keae336","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Integrating clinical and histological parameters into prognostic scores may enhance the prediction of progression to kidney failure in anti-neutrophil cytoplasm antibodies-associated vasculitis (AAV). This study aimed to evaluate the prognostic performance of histological classifications and scoring systems for kidney survival in AAV.</p><p><strong>Methods: </strong>This retrospective cohort study included 101 AAV patients with kidney involvement diagnosed by biopsy and followed for ≥12 months. The main outcome was the time to kidney failure. The prognostic performance of each histological and prognostic score was evaluated using Harrell's C statistic and Akaike's Information Criteria.</p><p><strong>Results: </strong>Among the 101 patients, 37 progressed to kidney failure over a median follow-up of 75 months (IQR 39-123). The Harrell's C statistic was 0.702 (0.620-0.784), 0.606 (0.473-0.738), 0.801 (0.736-0.867), 0.782 (0.706-0.858) and 0.817 (0.749-0.885) for the EUVAS/Berden classification, Mayo Clinic Chronicity Score, Percentage of ANCA Crescentic Score (PACS), ANCA renal risk score (ARRS), and the improved ANCA kidney risk score (AKRiS), respectively. The AKRiS best discriminated the risk of kidney failure progression among subgroups. The AKRiS performance decreased with longer follow-up intervals. Adding the peak estimated glomerular filtration rate attained post-therapy improved the AKRiS performance at all follow-up intervals. Kidney relapses precipitated kidney failure in 71% of cases that progressed after the first year of follow-up.</p><p><strong>Conclusion: </strong>The novel AKRiS enhances the prediction of kidney failure in AAV with kidney involvement. As the prognostic yield of AKRiS decreases over time, a second calculation of AKRiS, including post-therapy kidney function, may improve its long-term performance.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"1981-1988"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keae336","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Integrating clinical and histological parameters into prognostic scores may enhance the prediction of progression to kidney failure in anti-neutrophil cytoplasm antibodies-associated vasculitis (AAV). This study aimed to evaluate the prognostic performance of histological classifications and scoring systems for kidney survival in AAV.

Methods: This retrospective cohort study included 101 AAV patients with kidney involvement diagnosed by biopsy and followed for ≥12 months. The main outcome was the time to kidney failure. The prognostic performance of each histological and prognostic score was evaluated using Harrell's C statistic and Akaike's Information Criteria.

Results: Among the 101 patients, 37 progressed to kidney failure over a median follow-up of 75 months (IQR 39-123). The Harrell's C statistic was 0.702 (0.620-0.784), 0.606 (0.473-0.738), 0.801 (0.736-0.867), 0.782 (0.706-0.858) and 0.817 (0.749-0.885) for the EUVAS/Berden classification, Mayo Clinic Chronicity Score, Percentage of ANCA Crescentic Score (PACS), ANCA renal risk score (ARRS), and the improved ANCA kidney risk score (AKRiS), respectively. The AKRiS best discriminated the risk of kidney failure progression among subgroups. The AKRiS performance decreased with longer follow-up intervals. Adding the peak estimated glomerular filtration rate attained post-therapy improved the AKRiS performance at all follow-up intervals. Kidney relapses precipitated kidney failure in 71% of cases that progressed after the first year of follow-up.

Conclusion: The novel AKRiS enhances the prediction of kidney failure in AAV with kidney involvement. As the prognostic yield of AKRiS decreases over time, a second calculation of AKRiS, including post-therapy kidney function, may improve its long-term performance.

ANCA相关性血管炎肾脏存活率的临床和组织学预后评分。
目的:将临床和组织学参数整合到预后评分中可提高抗中性粒细胞胞浆抗体相关性血管炎(AAV)肾衰竭进展的预测能力。本研究旨在评估组织学分类和评分系统对AAV肾脏存活率的预后效果:这项回顾性队列研究纳入了101名经活检确诊肾脏受累并随访≥12个月的AAV患者。主要结果是出现肾衰竭的时间。使用哈雷尔C统计量和阿凯克信息标准评估了各组织学和预后评分的预后效果:结果:101 名患者中,37 人在中位随访 75 个月(IQR 39-123)后发展为肾衰竭。哈雷尔 C 统计量分别为 0.702(0.620-0.784)、0.606(0.473-0.738)、0.801(0.736-0.867)、0.782(0.706-0.858)和 0.817(0.749-0.885)。EUVAS/Berden分类、梅奥诊所慢性病评分、ANCA新月体百分比评分(PACS)、ANCA肾脏风险评分(ARRS)和改进的ANCA肾脏风险评分(AKRiS)分别为0.801(0.736-0.867)、0.782(0.706-0.858)和0.817(0.749-0.885)。AKRiS 对各亚组肾衰竭进展风险的判别能力最强。随访时间越长,AKRiS的表现越差。增加治疗后达到的估计肾小球滤过率峰值可改善所有随访间隔的 AKRiS 性能。71%的病例在随访一年后病情恶化,肾脏复发导致肾衰竭:结论:新型 AKRiS 提高了对肾脏受累的 AAV 肾衰竭的预测能力。由于 AKRiS 的预后效果会随着时间的推移而降低,对 AKRiS 进行第二次计算,包括治疗后的肾功能,可能会提高其长期效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Rheumatology
Rheumatology 医学-风湿病学
CiteScore
9.40
自引率
7.30%
发文量
1091
审稿时长
2 months
期刊介绍: Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press. Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信